A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 In Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Principal Investigator (?)
This phase 2 clinical study will be a randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.
Nitto Denko Corporation
Available at the following location(s)